Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-Blind, Randomized, Monocentric Phase II Trial to Explore the Safety and Rabies-Neutralizing Activity of Combined Administration of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin Plus Rabies Vaccine in Simulated Rabies Post-Exposure Prophylaxis in Children and Adolescents.

Next Previous
Trial Profile

A Single-Blind, Randomized, Monocentric Phase II Trial to Explore the Safety and Rabies-Neutralizing Activity of Combined Administration of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin Plus Rabies Vaccine in Simulated Rabies Post-Exposure Prophylaxis in Children and Adolescents.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Mar 2012

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Foravirumab (Primary) ; Rabies immune globulin; Rabies vaccine
  • Indications Rabies
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Crucell

Most Recent Events

  • 20 Oct 2009 Results have been presented in a Crucell media release.
  • 24 Jun 2009 Status changed from active, no longer recruiting to completed.
  • 27 May 2008 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top